BioCentury
ARTICLE | Clinical News

Trabedersen: Phase III discontinued

June 11, 2012 7:00 AM UTC

In January, Antisense terminated the open-label, international Phase III SAPPHIRE trial of trabedersen for second-line treatment of anaplastic astrocytoma or secondary glioblastoma (GBM) due to slow patient recruitment. The company said the delays were due to the reduced the number of patients diagnosed with anaplastic astrocytoma following changes by the World Health Organization in the histopathological grading of the disease. Additionally, Antisense said advances in the standard of care (SOC) for first-line therapy for the indication reduced the number of patients who received radiotherapy, an inclusion criterion for the trial. The company said there were no safety concerns for trabedersen. Antisense said it is still pursuing trabedersen as first-line therapy for GBM and pancreatic cancer in combination with SOC. ...